PACE was a pivotal phase 2 trial that evaluated the safety and efficacy of ponatinib at an initial dose of 45 mg in patients with heavily pretreated CML or Ph+ ALL with resistance or unacceptable side effects to 2G TKI treatment or with the BCR::ABL1 T315I mutation.9, 11. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.